Litcius/Paper detail

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05

Charles E. Geyer, Y.H. Park, Z-M Shao, Chiun‐Sheng Huang, Carlos H. Barrios, Judith A. Abraham, Ana Muntañola Prat, N. Niikura, M. Untch, S-A. Im, W. Li, Huili Li, Yibin Wang, Hanyu Yao, S-B. Kim, E. Mathias, Yusuke Sato, Wei Lü, Hanan Abdel‐Monem, Sibylle Loibl

2025Annals of Oncology12 citationsDOI

Topics & Concepts

MedicineTrastuzumab emtansineOncologyInternal medicineTrastuzumabNeoadjuvant therapyInterim analysisBreast cancerHuman Epidermal Growth Factor Receptor 2DiseaseChemotherapyInterimClinical trialRisk factorClinical endpointStandard of carePhases of clinical researchEpidermal growth factor receptorMinimal residual diseaseCancerResidual riskMetastatic breast cancerGynecologyLapatinibHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesAdvanced Breast Cancer Therapies
LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05 | Litcius